CJC-1295 and Ipamorelin are not the same peptide. They belong to different drug classes, act on different receptors, and have distinct half-lives. The reason they’re so often confused is that clinics frequently prescribe them together as a combination product, sometimes written as “CJC-1295/Ipamorelin” on a single vial label. That shorthand makes it easy to assume they’re one substance. In reality, they’re two separate compounds that work through complementary pathways to stimulate growth hormone release.
How CJC-1295 Works
CJC-1295 is a synthetic version of growth hormone-releasing hormone (GHRH), the signal your hypothalamus naturally sends to tell your pituitary gland to produce growth hormone. It binds to the same receptor that natural GHRH uses and essentially amplifies that “make more growth hormone” message. Research published in the American Journal of Physiology found that CJC-1295 not only raises growth hormone levels but also increases the number of growth hormone-producing cells in the pituitary itself, suggesting it has a deeper effect on the gland’s capacity over time.
One of CJC-1295’s defining features is how long it lasts compared to natural GHRH. The version with a chemical attachment called DAC (Drug Affinity Complex) binds to albumin, a protein in your blood, after injection. This extends its half-life to roughly 6 to 8 days, meaning a single dose keeps working for about a week. The version without DAC, often called Mod GRF 1-29, has a much shorter half-life of around 30 minutes. When clinics pair CJC-1295 with Ipamorelin, they typically use the no-DAC version so both peptides can be timed together.
How Ipamorelin Works
Ipamorelin belongs to an entirely different class called growth hormone-releasing peptides (GHRPs). Instead of mimicking GHRH, it mimics ghrelin, the hormone your stomach produces when you’re hungry. Ipamorelin activates ghrelin receptors on the pituitary gland, triggering growth hormone release through a separate signaling pathway from the one CJC-1295 uses.
What makes Ipamorelin stand out from older ghrelin-mimicking peptides is its selectivity. Earlier compounds in the same class, like GHRP-6, stimulated growth hormone but also raised cortisol (a stress hormone) and prolactin. Ipamorelin releases growth hormone with high potency while leaving cortisol and prolactin levels largely unchanged. A study in the European Journal of Endocrinology described it as “the first selective growth hormone secretagogue,” meaning it triggers growth hormone without the hormonal side effects that made earlier peptides less appealing. Its half-life sits around two hours, considerably longer than the no-DAC version of CJC-1295.
Why They’re Used Together
Because CJC-1295 and Ipamorelin stimulate growth hormone through two independent pathways, combining them produces a stronger pulse of growth hormone than either one alone. Think of it like pressing two different buttons that both lead to the same outcome. CJC-1295 tells the pituitary to ramp up production through the GHRH receptor, while Ipamorelin triggers release through the ghrelin receptor. The result is a synergistic effect where the combined response exceeds what you’d get by simply adding their individual effects together.
This pairing also allows for lower doses of each peptide compared to using either one in isolation, which can reduce the likelihood of side effects. The combination is typically injected once daily, ideally before bed and at least two hours after your last meal. That timing matters because eating raises insulin, and insulin blunts the growth hormone response. Nighttime dosing also aligns with your body’s natural growth hormone rhythm, which peaks during deep sleep.
Side Effects and Tolerability
The combination can cause flushing, headache, drowsiness, dizziness, a temporary increase in heart rate, and injection site reactions like redness or pain. Flushing is one of the more commonly reported effects, particularly in the first few weeks. The FDA has flagged CJC-1295 specifically for reports of increased heart rate and vasodilatory reactions (a sudden dilation of blood vessels that can cause warmth, redness, and a drop in blood pressure).
Ipamorelin is generally considered the gentler of the two, largely because of its selectivity. It doesn’t push cortisol or prolactin the way other growth hormone-releasing peptides do, which means fewer downstream hormonal disruptions. That said, neither peptide is without risk. The FDA has noted concerns about immunogenicity for both compounds, meaning the body could potentially mount an immune response to the injected peptides, particularly if impurities are present from the compounding process.
Regulatory Status in the U.S.
Neither CJC-1295 nor Ipamorelin is an FDA-approved drug. Both have been available through compounding pharmacies, which custom-mix medications that aren’t commercially manufactured. However, the FDA has placed both peptides under scrutiny. Ipamorelin acetate was added to the FDA’s list of bulk drug substances that may present significant safety risks in September 2023, partly because a published study identified serious adverse events, including death, when Ipamorelin was administered intravenously for gastrointestinal purposes. CJC-1295 is on the same list, with the FDA citing limited clinical data and the adverse cardiovascular events mentioned above.
This regulatory landscape is shifting. Compounding pharmacies that operate under Section 503B of the Federal Food, Drug, and Cosmetic Act face restrictions on producing these peptides, which has made access more uncertain for people who were previously using them. The practical impact is that availability varies by state and by pharmacy, and what you can get today may not be available next month.
Quick Comparison
- Drug class: CJC-1295 is a GHRH analog. Ipamorelin is a ghrelin receptor agonist (GHRP).
- Receptor target: CJC-1295 activates the GHRH receptor. Ipamorelin activates the ghrelin receptor.
- Half-life: CJC-1295 without DAC lasts about 30 minutes. Ipamorelin lasts about 2 hours. CJC-1295 with DAC lasts 6 to 8 days.
- Cortisol and prolactin: CJC-1295 can raise both modestly. Ipamorelin has minimal effect on either.
- Common side effects: CJC-1295 is more associated with flushing and heart rate increases. Ipamorelin is generally better tolerated.
- FDA approval: Neither is approved. Both are flagged for potential safety concerns when compounded.